Natus Medical (NASDAQ:NTUS) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

90.8% of Natus Medical shares are owned by institutional investors. Comparatively, 10.4% of electroCore shares are owned by institutional investors. 1.7% of Natus Medical shares are owned by company insiders. Comparatively, 43.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Natus Medical and electroCore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Natus Medical -7.38% 10.73% 6.61%
electroCore N/A -90.27% -80.15%

Analyst Ratings

This is a summary of current recommendations and price targets for Natus Medical and electroCore, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natus Medical 0 0 0 0 N/A
electroCore 0 2 3 0 2.60

electroCore has a consensus price target of $13.50, indicating a potential upside of 618.09%. Given electroCore’s higher probable upside, analysts plainly believe electroCore is more favorable than Natus Medical.

Valuation & Earnings

This table compares Natus Medical and electroCore’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natus Medical $530.89 million 2.11 -$22.93 million $1.42 23.14
electroCore $990,000.00 56.19 -$55.82 million ($1.19) -1.58

Natus Medical has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Natus Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, electroCore has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

electroCore Company Profile

electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.